First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
Sikander Ailawadhi(Jacksonville College), Yifan Zhai(Unknown), Asher Chanan‐Khan(WinnMed), Marina Konopleva(Albert Einstein College of Medicine), H. Miles Prince(Peter MacCallum Cancer Centre), Zhicong He(Pharmaxis (Australia)), Constantine S. Tam(The Alfred Hospital), Danielle M. Brander(Duke University), Bo Huang(Inserm), David A. Rizzieri(Duke University), Zhiyan Liang, Matthew S. Davids(Dana-Farber Cancer Institute), Costas K. Yannakou(Epworth Hospital), Masa Lasica(St Vincent's Hospital Melbourne), Dajun Yang(Ascendis Pharma (Denmark)), Mingyu Li, Ming‐De Lu(Sun Yat-sen University), Boyd Mudenda, Zi Chen(Dartmouth College), Mohammad Ahmad
Cited by 25
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k